Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Results
Phase 3
This trial looked at quizartinib for acute myeloid leukaemia (AML) that had got worse during treatment or come back after treatment.
It was open for people to join between 2014 and 2017. The team published results in 2019 and 2021. There is a link to more information in the ‘Summary of results’ section below.
Recruitment start: 7 May 2014
Recruitment end: 13 September 2017
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Nigel Russell
Daiichi Sankyo
NIHR Clinical Research Network: Cancer
Last reviewed: 21 April 2024
CRUK internal database number: 12471
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
